The Comparative Efficacy and Safety of Entecavir and Lamivudine in Patients with HBV-Associated Acute-on-Chronic Liver Failure: A Systematic Review and Meta-Analysis

Table 3

Efficacy comparison of entecavir and lamivudine for dichotomous outcomes.

Outcome of interest	Number of studies	Entecavir		Lamivudine		Effect estimate		Heterogeneity
		Sample size	Events	Sample size	Events	OR (95% CI)	value	(%)	value
Overall survival
1 month	5	249	216	255	209	1.52 (0.92, 2.52)	0.1	0	0.97
2 months	4	186	135	184	120	1.48 (0.94, 2.32)	0.09	0	0.87
3 months	6	318	216	319	214	1.06 (0.75, 1.48)	0.75	0	0.87
6 months	3	193	143	214	158	0.98 (0.61, 1.57)	0.94	0	0.38
12 months	5	344	290	349	269	1.79 (1.17, 2.75)	0.008	0	0.76
HBV DNA negative
1 months	6	382	251	353	155	2.85 (2.06, 3.94)	<0.00001	0	0.74
3 months	3	236	204	229	148	3.49 (2.20, 5.53)	<0.00001	0	0.83
12 months	3	215	208	201	156	8.61 (3.79, 19.59)	<0.00001	0	0.84
Recurrence of HBV	4	154	0	165	18	0.07 (0.01, 0.40)	0.003	0	0.93

OR: odds ratio; CI: confidence interval.